Specialties
- Hematology/Medical Oncology
Area of focus i
- Melanoma
- Kidney cancer (renal cancer)
- Sarcoma
Affiliated with
LocationPhone
1240 S Cedar Crest Blvd
Suite 401
Allentown, PA 18103-6218
United States
Description
This is not a treatment study. This study involves collecting information about participant's treatment with zoledronic acid as well as their general health and medical history, oral health and dental history, and pain assessment through questionnaires. This information will be collected every six months for up to three years. Participants who develop ONJ will be asked to provide the information listed above every three months for up to three years. Participants with ONJ will also be asked questions about their condition and what is being used to treat it.
Eligibility
Inclusion Criteria
must have bone metastasis from multiple myeloma, solid tumors, or other malignancy
must be planning to receive zoledronic acid for metastatic bone disease within 30 days after registration
No pre-existing diagnosis of ONJ
No history of radiation to the maxillofacial area
Must be willing and physically able to comply with the study procedures and assessments
Doctor(s) Running This Study